{"name":"Design Therapeutics, Inc.","slug":"design-tx","ticker":"DSGN","exchange":"NASDAQ","domain":"designtx.com","description":"Design Therapeutics, Inc. (DSGN) is a genetic medicines company focused on developing therapies for rare genetic diseases. The company's pipeline includes treatments for Duchenne muscular dystrophy and other genetic disorders. With a strong focus on gene editing and gene therapy, DSGN aims to revolutionize the treatment of genetic diseases. As a relatively new player in the biotech industry, DSGN is still building its presence and pipeline.","hq":"Carlsbad, CA","founded":0,"employees":"","ceo":"Joao Siffert","sector":"Genetic Medicines / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$320M","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2034-06-01","label":"DMD-101 patent cliff ($0.0B at risk)","drug":"DMD-101","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"DT-168","genericName":"DT-168","slug":"dt-168","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"DT-168","genericName":"DT-168","slug":"dt-168","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[{"date":"2024-02-27","type":"earnings","headline":"Design Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Design Therapeutics, Inc. (DSGN) today reported its financial results for the fourth quarter and full year 2023. The company reported a net loss of $43.4 million for the fourth quarter and $145.4 million for the full year 2023.","drugName":"","sentiment":"neutral"},{"date":"2023-11-15","type":"deal","headline":"Design Therapeutics Announces Collaboration with the Muscular Dystrophy Association","summary":"Design Therapeutics, Inc. (DSGN) today announced a collaboration with the Muscular Dystrophy Association (MDA) to advance the development of its gene therapy for Duchenne muscular dystrophy.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxQWDZBRjYtczNJLWF1emN1QkEyekhMa3Y1SE9LQnVkdi1TWEg4YlhIYmFHMk9CWmRtTGUxNEJjOHEzTGN4Y2RkcVl3NmNKN0VnMXBsRlJKQ25YZDBGYWI0dEszaUZPclVNMXlEM3drTE9UOWxnblM5aEFYY1FkYWpiUGdQcVVJSlUyOFR6cVhLLV9UYWd4Z0l3VnBnSWgzM1k0MElHRXo2U2lSeHFfaWlsVjRzN0t0eWVY?oc=5","date":"2026-04-01","type":"pipeline","source":"Stock Titan","summary":"Director David Shapiro granted 67,500 DSGN stock options (DSGN) - Stock Titan","headline":"Director David Shapiro granted 67,500 DSGN stock options (DSGN)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAJBVV95cUxOMl9xSEpkeUExbFRIYy1ZbkV0a0ZmYVBGR24tOVNVekpqQXl4UE40UWRhZ0JoLTBDNy1GT1NlYmxTVGpfZlFIcFg3WmRfSXNmaDRJQXUyXzdxdlJtc0V4Vm1HOE9lUXBsWThqMldzNy1iZUZSWGV4NUp4V25kN1c3Y3N5VkhBek9tLThqS1I5LTVscVNXU1ZjODVhUkJJMVduUlpRY3FXX002Y0RlR3pCQ2RmTzlWSkExRDdkbW5kR2FJMURUZVRld3Z2X1hyMEJHczVxRmY2ZmNoTmZVWEVFYUJUOU45azh0OHgxVGg3bTVnT1B3cXJaQkN3X0JYU2xBREo0c0R3OXJ4cS10WUt4bmRXYWtsNmU4dW9uRHBwaUc?oc=5","date":"2026-03-11","type":"pipeline","source":"The Globe and Mail","summary":"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Design Therapeutics (DSGN) and Vertex Pharmaceuticals (VRTX) - The Globe and Mail","headline":"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Design Therapeutics (DSGN) and Vertex Pharmaceuticals (VRTX)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxNS2wyQlFITTJ2b2k1ZUR5V0gtdUowRnVFcTRlNXl3S2hFaW9fZzVZazlCRGtCVG5zOWk4WVlFRTdZZE1Fc0dnbzNHSkw5WnhxQUpCeDV4amlMVzhELVRJb1c0anBEbXdmRFhkMjJmYm1Ua21STloyS0hIdHlNVmpRd0o1bFhVRDF6QmVQQ2FFNm8zN2NQLWloMExPeFIxYjNYRGhYNHhLNzllRFU?oc=5","date":"2026-01-02","type":"pipeline","source":"Kalkine Media","summary":"Design Therapeutics Inc (NASDAQ:DSGN) Nasdaq Index Genetic Focus - Kalkine Media","headline":"Design Therapeutics Inc (NASDAQ:DSGN) Nasdaq Index Genetic Focus","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-11-25","type":"pipeline","source":"simplywall.st","summary":"Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth - simplywall.st","headline":"Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAJBVV95cUxNUTFwbnUwQkY2eGdCSm1WdHJPWUlCUVF2ZlFDQ1J5am80NkdBdXltampRR1pBdTc2S3BXT1lTTnFEOWRTdFc3QTdjaFZPZTItV3dLYy1JeWRESE5rX3gydXlHUzJKMGFVd295THVXSkpDQkF4OEFlYjR0MVF5SXlxVnIzeG9BaWg3dE96WlowaFN0cXBOMWx0ajRsQ1FUMjNOWFU3U3NkZkxFbFN5MHJSN1Q1ejhDX2JPdE1nNTBfXzhjT252QnAySlI0ejRreXZMVE5ONDNvbTRxanlYNjNVaFFLYVBYQVMzSVhrRlJXb2w3ZjJQRlEyZUQweDl5OWRZQ3RBMnNXdV8?oc=5","date":"2025-11-20","type":"earnings","source":"Benzinga","summary":"Nutex Health Posts Strong Q3 Results, Joins PACS Group, Walmart, Cerence And Other Big Stocks Moving High - Benzinga","headline":"Nutex Health Posts Strong Q3 Results, Joins PACS Group, Walmart, Cerence And Other Big Stocks Moving High","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiVEFVX3lxTE01UHhrS2ExZWhPV2QySEtubmpCQ2s1OW5FNGtsWWduZHk1bkhOLTRwX2EzMGdCdW1yNlhZQnYxaHM1SnNtcWFlVzFsUjg3aUlmWHYzUw?oc=5","date":"2025-05-10","type":"deal","source":"Intellectia AI","summary":"DSGN Forecast — Price Prediction for 2026. Should I Buy DSGN? - Intellectia AI","headline":"DSGN Forecast — Price Prediction for 2026. Should I Buy DSGN?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxQVUNzOGNXUHdUNmRrdllpSXBPbDIwQjY2enJZekZPRjNFNVZuZkZhQ01FdGJ4all2ZldseHdmMkhrZlVRR2NJYUJaQ0JzV0lGczhDMHRDSHN4anduRms4ZXlfeUtpVlMwZEFscVE3aXVTM25vdkd6Q0NDM3MzRm1uZG1pOVRyRVMzeUpES1VnSWs5LXFlMjNpV21KamtsbVk4NGF5OWlR?oc=5","date":"2025-01-30","type":"pipeline","source":"Seeking Alpha","summary":"Design Therapeutics: Not A Complete Washout Despite Setback - Seeking Alpha","headline":"Design Therapeutics: Not A Complete Washout Despite Setback","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiUEFVX3lxTFB3cjBBd2FjZmwtMmJ4bDlsN3dmc1gyd0J4SjNENEN2aWdDSFh6bUpjakV4aHM3a0ZkZ2ZVUjd1VkRZN1FRT3l6cVp1Z1VBRUc5?oc=5","date":"2024-01-15","type":"pipeline","source":"CNN","summary":"symbol__ Stock Quote Price and Forecast - CNN","headline":"symbol__ Stock Quote Price and Forecast","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiXEFVX3lxTE1zM0FhbHUza2RUSjlaUWRkVXlReExrZkUyQkNNUWo4b3dXaXR6WlZFTEllZmcyd2hlS0tVbl9mMTZDS3ZIWnRFUWtMcmhFNkdNMVY3bDdSV2J5ZDk3?oc=5","date":"2021-03-26","type":"pipeline","source":"Yahoo! Finance Canada","summary":"Design Therapeutics, Inc. (DSGN) Options Chain - Yahoo! Finance Canada","headline":"Design Therapeutics, Inc. (DSGN) Options Chain - Yahoo! Finance Canada","sentiment":"neutral"}],"patents":[{"drugName":"DMD-101","drugSlug":"dmd-101","patentNumber":"","type":"Patent Cliff","expiryDate":"2034-06-01","territory":"US","annualRevenue":0}],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Sarepta Therapeutics, Inc. (SRPT)","Pfizer Inc. (PFE)","Biogen Inc. (BIIB)"],"therapeuticFocus":["Rare Genetic Diseases","Gene Editing","Gene Therapy"],"financials":null,"yahoo":null}